November 18, 2014
Novo Nordisk A/S has agreed to pay $19 million to settle a putative class action in Michigan federal court accusing it of attempting to monopolize the market for popular diabetes treatment Prandin by pursuing sham infringement litigation against generic-drug makers.
June 01, 2010
Novo Nordisk A/S has been slapped with a putative class action that accuses it of attempting to monopolize the market for popular diabetes treatment Prandin by pursuing sham infringement litigation against generic-drug makers.